Novel targeted therapies in the treatment of soft-tissue sarcomas

Expert Review of Anticancer Therapy

Volumn 10, Issue 8, 2010, Pages 1303-1311

  Chao, Joseph ^a   Chow, Warren A ^a   Somlo, George ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

angiogenesis; deforolimus; IGF 1 receptor; imatinib; mTOR; nelfinavir; sarcoma; sorafenib; sunitinib; tyrosine kinase inhibitors

Indexed keywords

BEVACIZUMAB; DEFOROLIMUS; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; NELFINAVIR; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C RECEPTOR; SORAFENIB; SUNITINIB;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; DRUG EFFICACY; GASTROINTESTINAL STROMAL TUMOR; GENE TARGETING; HISTOPATHOLOGY; HUMAN; LEIOMYOSARCOMA; PROTEIN EXPRESSION; REVIEW; SOFT TISSUE SARCOMA; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PROTEIN KINASE INHIBITORS; SARCOMA; TREATMENT OUTCOME;

EID: 77956250384     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.100     Document Type: Review

References (63)

1. World Health Organization Classification of Tumours. In: Pathology and Genetics of Tumours of Soft Tissue and Bone (5th Edition). Fletcher CD, Unni KK, Mertens F (Eds). IARC Press, Lyon, France (2002).
2. Edmonson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J. Clin. Oncol. 11(7), 1269-1275 (1993).
3. Antman K, Crowley J, Balcerzak SP et al. An intergroup Phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna inadvanced soft tissue and bone sarcomas. J. Clin. Oncol. 11(7), 1276-1285 (1993).
4. Issels RD, Lindner LH, Verweij J et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised Phase 3 multicentre study. Lancet Oncol. 11(6), 561-570 (2010).
5. Maki RG, Wathen JK, Patel SR et al. Randomized Phase II Study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J. Clin. Oncol. 25(19), 2755-2763 (2007).
6. Shor A, Agresta S, D'Amato G, Sondak VK. Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas. Cancer Control 15(1), 47-54 (2008).
7. Delattre O, Zucman J, Plougastel B et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359(6391), 162-165 (1992).
8. Borden EC, Baker LH, Bell RS et al. Soft tissue sarcomas of adults. Clin. Cancer Res. 9(6), 1941-1956 (2003)
9. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J. Clin. Oncol. 22(18), 3813-3825 (2004).
10. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347(7), 472-480 (2002).
11. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol. 26(4), 626-632 (2008).
12. DeMatteo RP, Ballman KV, Antonescu CR et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373(9669), 1097-1104 (2009).
13. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544), 1329-1338 (2006).
14. Desai J, Yassa L, Marqusee E et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann. Intern. Med. 145(9), 660-664 (2006).
15. Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370(9604), 2011-2019 (2007).
16. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 7(5), 332-344 (2007).
17. Wiebe L, Kasza KE, Maki RG et al. Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a Phase II trial of the University of Chicago Phase II Consortium. J. Clin. Oncol. (Meeting Abstracts), 26(Suppl. 15), 10502 (2008).
18. Ricotti E, Fagioli F, Garelli E et al. C-kit is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells. Blood 91(7), 2397-2405 (1998).
19. Landuzzi L, De Giovanni C, Nicoletti G et al. The metastatic ability of ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit. Am. J. Pathol. 157(6), 2123-2131 (2000).
20. Zwerner JP, May WA. PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors. Oncogene 20(5), 626-633 (2001).
21. Bond M, Bernstein ML, Pappo A et al. A Phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr. Blood Cancer 50(2), 254-258 (2008).
22. Chugh R, Wathen JK, Maki RG et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model. J. Clin. Oncol. 27, 3148-3153 (2009).
23. Bozzi F, Tamborini E, Negri T et al. Evidence for activation of KIT, PDGFRa, and PDGFRb receptors in the Ewing sarcoma family of tumors. Cancer 109(8), 1638-1645 (2007).
24. Chao J, Budd GT, Chu P et al. Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRa-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Anticancer Res. 30(2), 547-552 (2010).
25. George S, Merriam P, Maki RG et al. Multicenter Phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J. Clin. Oncol. 27(19), 3154-3160 (2009).
26. Das J, Chen P, Norris D et al. 2-aminothiazole as a novel kinase inhibitor template. structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6- [4-(2-hydroxyethyl)-1- piperazinyl)]-2- methyl-4-pyrimidinyl]amino)]-1,3- thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-SRC kinase inhibitor. J. Med. Chem. 49(23), 6819-6832 (2006).
27. Maki RG, D'Adamo DR, Keohan ML et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J. Clin. Oncol. 27(19), 3133-3140 (2009).
28. Ambrosini G, Cheema HS, Seelman S et al. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Mol. Cancer Ther. 7(4), 890-896 (2008).
29. Ryan CW, von Mehren M, Rankin CJ et al. Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505. J. Clin. Oncol. (Meeting Abstracts), 26(15 Suppl.) (2008) (Abstract 10532).
30. Sleijfer S, Ray-Coquard I, Papai Z et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). J. Clin. Oncol. 27(19), 3126-3132 (2009).
31. Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as theprincipal end-point for Phase II trials in soft-tissue sarcomas. Eur. J. Cancer 38(4), 543-549 (2002).
32. Thomas DG, Giordano TJ, Sanders D et al. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer 103(4), 830-838 (2005).
33. Blay J, Le Cesne A, Whelan J et al. Gefitinib in second line treatment of metastatic or locally advanced synovial sarcoma expressing HER1: a Phase II trial of EORTC Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. (Meeting Abstracts), 24(18 Suppl.) (2006) (Abstract 9517).
34. Holtkamp N, Malzer E, Zietsch J et al. EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro. Oncol. 10(6), 946-957 (2008).
35. Tabone-Eglinger S, Bahleda R, Cote J-F et al. Frequent EGFR positivity and overexpression in high-grade areas of human MPNSTs. Sarcoma 2008, 849156 (2008).
36. Keizman D, Issakov J, Meller I et al. Expression and significance of EGFR in malignant peripheral nerve sheath tumor. J. Neurooncol. 94(3), 383-388 (2009).
37. Albritton KH, Rankin C, Coffin CM et al. Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). J. Clin. Oncol. (Meeting Abstracts), 24(18 Suppl.), 9518 (2006).
38. Potti A, Ganti A, Tendulkar K et al. Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. J. Cancer Res. Clin. Oncol. 130(1), 52-56 (2004).
39. Yoon SS, Segal NH, Olshen AB, Brennan MF, Singer S. Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma. Ann. Oncol. 15(8), 1261-1266 (2004).
40. D'Adamo DR, Anderson SE, Albritton K et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J. Clin. Oncol. 23(28), 7135-7142 (2005).
41. Agulnik M, Okuno SH, Von Mehren M et al. An open-label multicenter Phase II study of bevacizumab for the treatment of angiosarcoma. J. Clin. Oncol. (Meeting Abstracts), 27(15 Suppl.) (2009) (Abstract 10522).
42. Yoon SS, Karl D, Rothrock C et al. Interim analysis of a Phase II study of neoadjuvant bevacizumab and radiation therapy for resectable soft tissue sarcomas. Proc. CTOS 15, 39179a (2009).
43. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441(7092), 437-443 (2006).
44. Okuno S. Mammalian target of rapamycin inhibitors in sarcomas. Curr. Opin. Oncol. 18(4), 360-362 (2006).
45. Pan CC, Chung MY, Ng KF et al. Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma. J. Pathol. 214(3), 387-393 (2008).
46. Wagner AJ, Malinowska-Kolodziej I, Morgan JA et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J. Clin. Oncol. 28(5), 835-840 (2010).
47. Okuno SH, Mahoney MR, Bailey HH et al. A multicenter Phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS). J. Clin. Oncol. (Meeting Abstracts), 24(18 Suppl.) (2006) (Abstract 9504).
48. Chawla SP, Tolcher AW, Staddon AP et al. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: update of Phase II trial. J. Clin. Oncol. (Meeting Abstracts), 25(18 Suppl.) (2007) (Abstract 10076).
49. Sankhala KK, Chawla SP, Iagaru A et al. Early response evaluation of therapy with AP23573 (an mTOR inhibitor) in sarcoma using [18F]2-fluoro-2-deoxy- d-glucose (FDG) positron emission tomography (PET) scan. J. Clin. Oncol. (Meeting Abstracts), 23(16 Suppl.) (2005) (Abstract 9028).
50. Iwenofu OH, Lackman RD, Staddon AP, Goodwin DG, Haupt HM, Brooks JSJ. Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod. Pathol. 21(3), 231-237 (2007).
51. Fürstenberger G, Senn H-J. Insulin-like growth factors and cancer. Lancet Oncol. 3(5), 298-302 (2002).
52. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4(7), 505-518 (2004).
53. Ahlén J, Wejde J, Brosjö O et al. Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma. Clin. Cancer Res. 11(1), 206-216 (2005).
54. Scotlandi K, Picci P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr. Opin. Oncol. 20(4), 419-427 (2008).
55. Kolb E, Gorlick R. Development of IGF-IR inhibitors in pediatric sarcomas. Curr. Oncol. Rep. 11(4), 307-313 (2009).
56. Scotlandi K, Manara MC, Nicoletti G et al. antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 65(9), 3868-3876 (2005).
57. Olmos D, Okuno S, Schuetze SM et al. Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma. J. Clin. Oncol. (Meeting Abstracts), 26(15 Suppl.) (2008) (Abstract 10501).
58. Patel S, Pappo A, Crowley J et al. A SARC global collaborative Phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas. J. Clin. Oncol. (Meeting Abstracts), 27(15 Suppl.) (2009) (Abstract 10503).
59. Chow WA, Jiang C, Guan M. Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol. 10(1), 61-71 (2009).
60. Chow WA, Guo S, Valdes-Albini F. Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1. Anti-Cancer Drugs 17(8), 891-903 (2006).
61. Chow WA, Mott M, Hepner E et al. Early evidence of clinical activity for liposarcoma with the HIV protease inhibitor nelfinavir. Proc. CTOS 13, 783a (2007).
62. Zhang WE, Kolb EA. Reolysin®, an unmodified reovirus, has significant anti-tumor activity in childhood sarcomas. AACR Meeting Abstracts 2006(1) (2006) (Abstract 1017b)
63. Mita M, Sankhala K, Sarantopoulos J et al. Phase II study of intravenous reolysin (wild type reovirus) in patients with bone and soft tissue sarcoma metastatic to lung. Proc. CTOS 15, 39323a (2009).